Clinical Cancer Research, Vol 4, Issue 5 1153-1158, Copyright © 1998 by American Association for Cancer Research

ARTICLES

Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors

CJ Gerrits, H Burris, JH Schellens, JR Eckardt, AS Planting, ME van der Burg, GI Rodriguez, WJ Loos, V van Beurden, I Hudson, S Fields, DD Von Hoff and J Verweij
Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital, The Netherlands.

Prolonged exposure to topotecan (TPT) in in vitro experiments and in vivo studies in animals yielded the highest antitumor efficacy. An oral bioavailability of TPT of 32-44% enables convenient prolonged administration. Because of unpredictable diarrhea in the third week of the twice daily (b.i.d.) 21-day schedule of p.o. administered TPT and the finding of optimal down-regulation of topoisomerase I level after 10-14 days in mononuclear peripheral blood cells, a shorter period of administration (10 days) was chosen for Phase I and pharmacological studies of oral administration of TPT. Adult patients with malignant solid tumors that were refractory to standard forms of chemotherapy were entered. Two dose schedules were studied: once daily (o.d.) and b.i.d. administration for 10 days every 3 weeks. TPT o.d. for 10 days was studied at dose levels 1.0, 1.4, and 1.6 mg/m2/day, and dose levels were 0.5, 0.6, 0.7, and 0.8 mg/m2 with the 10-day b.i.d. schedule. Pharmacokinetics were performed on days 1 and 8 of the first course using a validated high-performance liquid chromatographic assay and noncompartmental pharmacokinetic methods. Nineteen patients were entered in the 10-day o.d. schedule, with a total of 48 courses given. Dose-limiting toxicity (DLT) was reached at 1.6 mg/m2/day and consisted of common toxicity criteria (CTC) grade IV thrombocytopenia and CTC grade III diarrhea. The maximum tolerated dose was 1.4 mg/m2/day. In the 10-day b.i.d. administration of TPT, a total of 64 courses were studied in 20 patients. DLT was reached at a dose of 0.8 mg/m2 b.i.d. and consisted of CTC grade IV myelosuppression and CTC grade IV diarrhea. The maximum tolerated dose was 0.7 mg/m2 b.i.d. Nonhematological toxicities with both schedules included mild nausea and vomiting, fatigue, and anorexia. Pharmacokinetics revealed a substantial variation of the area under the plasma concentration-time curve of TPT lactone in both schedules. Significant correlations were observed between the myelotoxicity parameters and the area under the plasma concentration-time curve at day 1 of TPT lactone o.d. and b.i.d. The DLT of 10 daily administrations of oral topotecan every 3 weeks consisted of a combination of myelosuppression and diarrhea for both schedules studied. The recommended doses for Phase II studies are 1.4 mg/m2/day for 10 days for the o.d. administration and 0.7 mg/m2 for the b.i.d. schedule.

This article has been cited by other articles:

				M. O'Brien, J. Eckardt, and R. Ramlau Recent Advances with Topotecan in the Treatment of Lung Cancer Oncologist, October 1, 2007; 12(10): 1194 - 1204. [Abstract] [Full Text] [PDF]

				I. E.L.M. Kuppens, E. O. Witteveen, R. C. Jewell, S. A. Radema, E. M. Paul, S. G. Mangum, J. H. Beijnen, E. E. Voest, and J. H.M. Schellens A Phase I, Randomized, Open-Label, Parallel-Cohort, Dose-Finding Study of Elacridar (GF120918) and Oral Topotecan in Cancer Patients Clin. Cancer Res., June 1, 2007; 13(11): 3276 - 3285. [Abstract] [Full Text] [PDF]

				D. P. Lee, J. M. Skolnik, and P. C. Adamson Pediatric Phase I Trials in Oncology: An Analysis of Study Conduct Efficiency J. Clin. Oncol., November 20, 2005; 23(33): 8431 - 8441. [Abstract] [Full Text] [PDF]

				A. Rapisarda, J. Zalek, M. Hollingshead, T. Braunschweig, B. Uranchimeg, C. A. Bonomi, S. D. Borgel, J. P. Carter, S. M. Hewitt, R. H. Shoemaker, et al. Schedule-dependent Inhibition of Hypoxia-inducible Factor-1{alpha} Protein Accumulation, Angiogenesis, and Tumor Growth by Topotecan in U251-HRE Glioblastoma Xenografts Cancer Res., October 1, 2004; 64(19): 6845 - 6848. [Abstract] [Full Text] [PDF]

				N. C. Daw, V. M. Santana, L. C. Iacono, W. L. Furman, D. R. Hawkins, P. J. Houghton, J. C. Panetta, A. J. Gajjar, and C. F. Stewart Phase I and Pharmacokinetic Study of Topotecan Administered Orally Once Daily for 5 Days for 2 Consecutive Weeks to Pediatric Patients With Refractory Solid Tumors J. Clin. Oncol., March 1, 2004; 22(5): 829 - 837. [Abstract] [Full Text] [PDF]

				S. D. Baker, J. Verweij, E. K. Rowinsky, R. C. Donehower, J. H. M. Schellens, L. B. Grochow, and A. Sparreboom Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991-2001 J Natl Cancer Inst, December 18, 2002; 94(24): 1883 - 1888. [Abstract] [Full Text] [PDF]

				C. M.F. Kruijtzer, J. H. Beijnen, H. Rosing, W. W. ten Bokkel Huinink, M. Schot, R. C. Jewell, E. M. Paul, and J. H.M. Schellens Increased Oral Bioavailability of Topotecan in Combination With the Breast Cancer Resistance Protein and P-Glycoprotein Inhibitor GF120918 J. Clin. Oncol., July 1, 2002; 20(13): 2943 - 2950. [Abstract] [Full Text] [PDF]

				W. L. Furman, C. F. Stewart, M. Kirstein, J. L. Kepner, M. L. Bernstein, F. Kung, T. J. Vietti, C. P. Steuber, D. L. Becton, S. Baruchel, et al. Protracted Intermittent Schedule of Topotecan in Children With Refractory Acute Leukemia: A Pediatric Oncology Group Study J. Clin. Oncol., March 15, 2002; 20(6): 1617 - 1624. [Abstract] [Full Text] [PDF]

				W. J. Loos, H. Gelderblom, A. Sparreboom, J. Verweij, and M. J. A. de Jonge Inter- and Intrapatient Variability in Oral Topotecan Pharmacokinetics: Implications for Body-Surface Area Dosage Regimens Clin. Cancer Res., July 1, 2000; 6(7): 2685 - 2689. [Abstract] [Full Text]

				M. J.A. de Jonge, C. J.A. Punt, A. H. Gelderblom, W. J. Loos, V. van Beurden, A. S.Th. Planting, M. E.L. van der Burg, L. W.G.M. van Maanen, B. K. Dallaire, J. Verweij, et al. Phase I and Pharmacologic Study of Oral (PEG-1000) 9-Aminocamptothecin in Adult Patients With Solid Tumors J. Clin. Oncol., July 1, 1999; 17(7): 2219 - 2219. [Abstract] [Full Text] [PDF]